A MARCKS Effector Domain‐Derived Cytotoxic Peptide Induces Acute Tumor Cell Death
Cell Biochemistry and Function · 2025-11 · 43 (11)
DOI: 10.1002/cbf.70139 ↗At a glance
Journal article in Cell Biochemistry and Function, published online on 2025-11-05. Written by Yucai Wang and 4 co-authors. Institution: Institute of Molecular Immunology, Department of Biotechnology, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzh…. Major MEDLINE topics: Myristoylated Alanine-Rich C Kinase Substrate, Peptides, Antineoplastic Agents. Cited 1 times so far (Crossref); 37 references. Funded by: Chenguang Xu was supported by the National Natural Science Foundation of China (32170940, 82572100), the Guangdong Basic and Applied Basic Research Foundation….
Abstract (original language)
Peptide drugs, with their unique properties of specific therapeutic effects and minimal side effects, are a promising avenue in cancer treatment. The MARCKS effector domain (ED) peptide has been found to inhibit MARCKS function or induce cell death. In this study, we investigated the cytotoxic efficacy of the non‐phosphorylating MARCKS ED peptide with four serine (4S) of ED mutation to alanine (4 A) and with a transactivator of transcription (TAT) (termed 4A‐TAT) fusion to improve cell permeating. We found that the 4A‐TAT peptide caused acute and robust cytotoxicity against various tumor cell lines and had low toxicity to normal human B cells. Mechanistically, 4A‐TAT rapidly disrupts plasma membrane integrity via pore formation, leading to calcium dyshomeostasis and organelle dysfunction, and ultimately inducing non‐apoptotic cell death. In addition, the ED4A amino acid component is more critical than its order, and TAT is essential for the high sensitivity of cytotoxicity. Our study suggests that 4A‐TAT peptide shows acute and robust killing effects on tumor cells in vitro and in vivo, making it a potentially intriguing cytotoxic peptide for tumor treatment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Institute of Molecular Immunology, Department of Biotechnology, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
ORCID profiles: Chenguang Xu
Funding
- Chenguang Xu was supported by the National Natural Science Foundation of China (32170940, 82572100), the Guangdong Basic and Applied Basic Research Foundation…
Cite
APA
Wang, Y., Qiu, Y., Liu, D., Zhang, H., & Xu, C. (2025). A MARCKS Effector Domain‐Derived Cytotoxic Peptide Induces Acute Tumor Cell Death. Cell Biochemistry and Function, 43(11). https://doi.org/10.1002/cbf.70139
Vancouver
Wang Y, Qiu Y, Liu D, Zhang H, Xu C. A MARCKS Effector Domain‐Derived Cytotoxic Peptide Induces Acute Tumor Cell Death. Cell Biochemistry and Function. 2025;43(11). doi:10.1002/cbf.70139
BibTeX
@article{Wang2025,
author = {Wang, Yucai and Qiu, Yue and Liu, Decheng and Zhang, Hongyuan and Xu, Chenguang},
title = {A MARCKS Effector Domain‐Derived Cytotoxic Peptide Induces Acute Tumor Cell Death},
journal = {Cell Biochemistry and Function},
year = {2025},
volume = {43},
number = {11},
doi = {10.1002/cbf.70139}
}
EUVIMED